$3-Million Loss Reported by ICN Pharmaceuticals

ICN Pharmaceuticals Inc., the Costa Mesa parent of three public companies, reported a loss of $3 million, or 15 cents a share, for the second quarter, contrasted with net income of $3.2 million, or 21 cents a share, for last year’s second quarter.

Sales fell to $15.7 million from $170.1 million because ICN did not consolidate results from SPI Pharmaceuticals Inc., of which it owns 43%.

SPI, which has major Yugoslav operations, continues to be hurt by economic disintegration, currency devaluation and severe United Nations economic sanctions against Yugoslavia.

The company lost $1.9 million, or 10 cents a share, for the first six months of 1993, contrasted with a profit of $9.8 million, or 66 cents a share, for the 1992 first half. Sales dropped to $32.3 million from $312.5 million.